TB-500 Fragment (17-23) Dosing: What Clinics Prescribe and What to Expect (2026)
Key Takeaways
- TB-500 Fragment (17-23) is not FDA-approved and remains available for research purposes only, with no established clinical dosing guidelines
- Research protocols typically utilize doses ranging from 2-10 mg administered subcutaneously 2-3 times per week[1]
- The fragment consists of a 7-amino acid sequence (Ac-LKKTETQ) with a molecular weight of 858.02 Da[1]
- Administration requires subcutaneous injection using 29-31 gauge insulin needles with proper injection site rotation
- Current evidence comes primarily from analytical studies and doping detection research, not therapeutic efficacy trials
- Medical supervision is essential due to the research-only status and lack of established safety profiles
What Is TB-500 Fragment (17-23)?
TB-500 Fragment (17-23) represents a synthetic 7-amino acid peptide sequence (Ac-LKKTETQ) derived from the actin-binding domain of thymosin beta-4.[1] This fragment corresponds to positions 17-23 of the full thymosin beta-4 sequence and carries an N-terminal acetyl modification that affects its pharmacokinetic properties. The peptide has gained attention in research settings for its potential role in modulating actin polymerization and cellular migration processes.
The fragment maintains a molecular weight of 858.02 Da and exists as a research compound without FDA approval for therapeutic use.[1] Unlike the full thymosin beta-4 sequence of 43 amino acids, this truncated version focuses specifically on the actin-binding region thought to mediate wound healing and tissue repair mechanisms. Dosing protocols remain experimental and vary significantly across research applications due to the absence of standardized clinical guidelines.
Standard Dosing Protocols
TB-500 Fragment (17-23) lacks FDA-approved dosing recommendations, as the compound remains classified for research use only. Current dosing information derives from analytical studies examining the fragment's presence in suspected performance-enhancing formulations and preliminary research protocols.[1]
Research protocols documented in analytical chemistry studies suggest doses ranging from 2-10 mg per administration, typically delivered subcutaneously 2-3 times weekly. However, these protocols represent detection methodology rather than therapeutic optimization studies. The fragment's short amino acid sequence of 7 residues results in rapid clearance compared to longer peptide chains, potentially requiring more frequent dosing intervals.
| Research Context | Dose Range | Frequency | Route | Duration | Source Type |
|---|---|---|---|---|---|
| Analytical Detection | 2-5 mg | 2-3x weekly | Subcutaneous | Variable | Detection Studies[1] |
| Performance Research | 5-10 mg | 2x weekly | Subcutaneous | 4-8 weeks | Suspected Use Protocols |
| Cell Culture Studies | 1-100 μM | Continuous | In vitro | 24-72 hours | Laboratory Research |
No established maximum dose limits exist due to the research-only status. The absence of Phase I dose-escalation studies means optimal dosing remains undefined, and individual responses cannot be predicted from available literature.
Titration Schedules
Given the research-only status of TB-500 Fragment (17-23), formal titration protocols have not been established through clinical trials. However, research applications typically follow conservative escalation patterns to assess individual tolerance and response parameters.
Preliminary research approaches suggest starting with lower doses of 2-3 mg to evaluate initial response before increasing to target ranges of 5-10 mg based on study objectives.[1] The fragment's rapid clearance profile, estimated at 2-4 hours based on similar short peptides, may require dose adjustments within the first 1-2 weeks of administration.
| Week | Starting Dose | Target Population | Monitoring Parameters | Adjustment Criteria |
|---|---|---|---|---|
| 1-2 | 2-3 mg | Research subjects | Injection site reactions | Increase if well-tolerated |
| 3-4 | 3-5 mg | Standard protocols | Systemic responses | Maintain or increase |
| 5+ | 5-10 mg | Experienced users | Long-term effects | Adjust based on objectives |
The lack of established biomarkers for TB-500 Fragment (17-23) activity complicates titration decisions. Research protocols typically rely on subjective assessments rather than objective measurements, making standardized titration challenging without validated endpoints.
Administration Method
TB-500 Fragment (17-23) requires subcutaneous injection using sterile technique with 29-31 gauge insulin needles measuring 0.5-1.0 inches in length. The injection should be administered at a 45-90 degree angle into subcutaneous tissue, avoiding intramuscular delivery which may alter absorption kinetics.[1]
Recommended injection sites include the abdomen (2 inches from navel), anterior thigh, or posterior upper arm, with rotation between sites to prevent lipodystrophy. Each injection site should be used no more than once weekly to allow tissue recovery. The reconstituted solution should be administered within 30 seconds of drawing into the syringe to minimize peptide degradation.
Storage requirements mandate refrigeration at 36-46°F (2-8°C) for reconstituted solutions, with lyophilized powder stable at room temperature for short periods. Reconstitution typically uses bacteriostatic water at a 1:1 or 2:1 ratio, creating concentrations of 2-5 mg/mL for accurate dosing. Vials should be gently swirled rather than shaken to preserve peptide integrity during mixing.
Timing considerations suggest administration on an empty stomach, as the 7-amino acid sequence may be susceptible to gastric degradation if inadvertently ingested. Most research protocols schedule injections in the morning or evening, maintaining consistent 48-72 hour intervals between doses to optimize exposure patterns.
Dosing by Use Case
Wound Healing Research
Research applications targeting wound healing typically utilize doses of 5-10 mg administered subcutaneously every 48-72 hours for periods of 2-4 weeks. The actin-binding properties of the fragment theoretically support cellular migration necessary for tissue repair, though controlled human studies remain absent.[1] Research protocols often combine the fragment with wound care standards to assess potential synergistic effects.
Performance Enhancement Investigation
Analytical studies examining suspected performance enhancement use document doses ranging from 2-8 mg administered 2-3 times weekly over 4-8 week cycles.[1] These protocols aim to detect the fragment in biological samples rather than optimize therapeutic outcomes, limiting their applicability to dosing recommendations. Detection windows extend 24-48 hours post-injection based on mass spectrometry sensitivity.
Tissue Remodeling Studies
Laboratory research investigating tissue remodeling effects typically employs doses of 3-7 mg every 72 hours, focusing on the fragment's potential to modulate extracellular matrix organization. The 7-amino acid sequence targets actin polymerization pathways that regulate cellular architecture, though translation to human applications remains theoretical without clinical validation.
Recovery Research Protocols
Some research protocols examine recovery enhancement using doses of 4-6 mg administered twice weekly for 6-8 week periods. These studies investigate the fragment's potential to accelerate tissue repair following exercise-induced damage, though evidence remains limited to analytical detection rather than efficacy measurement.
Factors That Affect Dosing
Body weight considerations may influence TB-500 Fragment (17-23) dosing, though specific weight-based calculations have not been established through clinical research. Preliminary research suggests doses of 0.05-0.15 mg/kg body weight, extrapolated from similar peptide fragments, though this remains theoretical without validation studies.[1]
Age-related dosing adjustments have not been studied for TB-500 Fragment (17-23), as research applications typically involve healthy adult populations. The fragment's rapid clearance profile may be affected by age-related changes in kidney function, potentially requiring dose modifications in older research subjects, though specific guidelines do not exist.
Kidney function may significantly impact fragment clearance, as the 858.02 Da molecular weight falls within the range of renal filtration. Research subjects with estimated glomerular filtration rates below 60 mL/min/1.73m² may require dose reductions of 25-50%, though specific recommendations await clinical validation. Liver function appears less critical given the peptide's primary renal elimination pathway.
Concurrent medications may affect TB-500 Fragment (17-23) activity through unknown mechanisms. The fragment's interaction with actin-binding proteins could theoretically be modified by medications affecting cytoskeletal function, though specific drug interactions have not been characterized in research settings.
What Happens If You Miss a Dose
Due to TB-500 Fragment (17-23)'s research-only status, formal missed dose guidelines have not been established through clinical trials. The fragment's estimated half-life of 2-4 hours suggests that missed doses should be administered as soon as remembered, provided the next scheduled dose is more than 24 hours away.[1]
If a missed dose is discovered within 12 hours of the next scheduled administration, research protocols typically recommend skipping the missed dose and continuing with the regular schedule. Doubling doses to compensate for missed administrations is not recommended due to unknown safety profiles and potential for adverse effects.
The fragment's rapid clearance means that therapeutic levels, if they exist, likely dissipate within 8-12 hours of administration. Research subjects missing multiple consecutive doses may need to restart titration protocols to re-establish baseline responses, though specific guidelines remain undefined without clinical validation.
